Dariusz Pawlak

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

Jolanta Kunikowska, Leszek Królicki, Alicja Hubalewska‐Dydejczyk et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2011 · 234 citations · Full text

Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study

A Sankowski, Nina Seklecka, John Buscombe et al. · Annals of Oncology · 2009 · 170 citations

Medicine, Radionuclide Therapy, Phase Ii Study +8

Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)

Anna Sowa‐Staszczak, Dorota Pach, Robert Chrzan et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2011 · 106 citations · Full text

Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma

Leszek Królicki, Frank Bruchertseifer, Jolanta Kunikowska et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2018 · 104 citations

Neuro-oncology, Medicine, Pharmacology +11

Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue

Leszek Królicki, Frank Bruchertseifer, Jolanta Kunikowska et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2018 · 101 citations · Full text